Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
Jan 19, 2023, 07:30 ET – BREAKOUT Study is Palatin’s third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists – Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J., Jan. 19, 2023 …